Helen L Twigger

Title: Helen L Twigger: Innovator in Kinase Inhibitors

Introduction

Helen L Twigger is a prominent inventor based in Nottingham, GB. She has made significant contributions to the field of chemical compounds, particularly in the development of kinase inhibitors. With a total of three patents to her name, her work has the potential to impact various medical conditions.

Latest Patents

Helen's latest patents include "4-aminopyrrolopyrimidines as kinase inhibitors." These chemical compounds, along with their physiologically acceptable salts, serve as inhibitors of serine/threonine and tyrosine kinase activity. The kinases inhibited by these compounds are involved in immunologic, hyperproliferative, or angiogenic processes. Consequently, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. They can be utilized to treat cancer, hyperproliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders. Another significant patent is "Kinase inhibitors as therapeutic agents," which focuses on compounds that are useful as kinase inhibitors.

Career Highlights

Throughout her career, Helen has worked with notable companies such as BASF Aktiengesellschaft and Abbott GmbH & Co. KG. Her experience in these organizations has allowed her to develop her expertise in the field of chemical compounds and their applications in medicine.

Collaborations

Helen has collaborated with esteemed colleagues, including Paul Rafferty and David N Johnston. Their combined efforts have contributed to advancements in the understanding and application of kinase inhibitors.

Conclusion

Helen L Twigger's innovative work in the field of kinase inhibitors showcases her dedication to improving medical treatments. Her patents reflect her commitment to addressing critical health issues through scientific research and development.